Boston Scientific Boosts Portfolio - Analyst Blog NASDAQ Boston Scientific 's ( BSX ) coronary stent portfolio was boosted with the CE Mark approval of its Synergy everolimus-eluting platinum chromium stent. The product features everolimus drug coating which dissolves in three months, thus improving post ... |
